Teva Pharmaceutical Industries Limited (TEV) — Cash Flow-to-Debt Ratio
Teva Pharmaceutical Industries Limited (TEV) has a Cash Flow-to-Debt Ratio of 0.00x as of March 2026, meaning its operating cash flow of €-40.00 Million could theoretically repay 0% of its total liabilities (€31.81 Billion) in one year. Explore TEV strategic capital deployment ratio to see how much of total assets are deployed in long-term investments.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Teva Pharmaceutical Industries Limited Cash Flow-to-Debt Ratio (2015–2025)
Historical debt coverage capacity for Teva Pharmaceutical Industries Limited across 11 annual periods. Also explore TEV total assets for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for Teva Pharmaceutical Industries Limited (2015–2025)
Year-by-year debt coverage analysis for Teva Pharmaceutical Industries Limited. For market capitalisation and broader financial context, see Teva Pharmaceutical Industries Limited (TEV) total market value.
| Year | CF-to-Debt Ratio | Operating CF (EUR) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.05x | €1.65 Billion | €32.83 Billion | ▲ +35.3% |
| 2024 | 0.04x | €1.25 Billion | €33.61 Billion | ▲ +13.4% |
| 2023 | 0.03x | €1.16 Billion | €35.35 Billion | ▼ -27.3% |
| 2022 | 0.05x | €1.59 Billion | €35.31 Billion | ▲ +105.5% |
| 2021 | 0.02x | €798.00 Million | €36.42 Billion | ▼ -28.7% |
| 2020 | 0.03x | €1.22 Billion | €39.58 Billion | ▲ +74.2% |
| 2019 | 0.02x | €748.00 Million | €42.41 Billion | ▼ -67.6% |
| 2018 | 0.05x | €2.45 Billion | €44.89 Billion | ▲ +27.0% |
| 2017 | 0.04x | €2.23 Billion | €51.87 Billion | ▼ -36.2% |
| 2016 | 0.07x | €3.89 Billion | €57.90 Billion | ▼ -70.5% |
| 2015 | 0.23x | €5.54 Billion | €24.31 Billion | — |